Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Long-acting GLP-1 depot
- Development stage
- Preclinical
- Lead developer
- Optimeos Life Sciences
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
Long-acting GLP-1 depot is an investigational long-acting subcutaneous microparticle depot formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Optimeos Life Sciences using its proprietary Long-acting Inverse NanoCarrier (LINC) platform. The LINC platform utilizes microparticles optimized for the sustained, extracellular delivery of peptides over weeks to months. Designed to exhibit zero-order pharmacokinetics over 30 to 60 days, this depot formulation aims to provide constant GLP-1 exposure, thereby eliminating the high peak plasma levels (Cmax) associated with gastrointestinal side effects. It is being developed for the treatment of obesity and other metabolic diseases.
- Other names
- LINC GLP-1 depotLINC GLP-1R agonist depot
02
Targets
Beyond the preview
Go deeper on Long-acting GLP-1 depot.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long-acting GLP-1 depot.